Evidence map›Paper›PMID 42779796›Full record

ArticlebioRxiv : the preprint server for biology2026

Latent generative search unlocks de novo design of untapped biomolecular interactions at scale.

Kieran Didi, Danny Reidenbach, Matthew Penner, Supriya Ravichandran, Marshall Case, Mike Nichols, Erik Swanson, Alex Reis, Maggie Prescott, Yue Qian and 37 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

47 authors.

Kieran DidiNVIDIA Corporation, Santa Clara, CA, USA.ORCID 0000-0001-6839-3320
Danny ReidenbachNVIDIA Corporation, Santa Clara, CA, USA.ORCID 0000-0002-2973-8709
Matthew PennerUniversity of Cambridge, Cambridge, UK.
Supriya RavichandranManifold Bio, Boston, MA, USA.
Marshall CaseManifold Bio, Boston, MA, USA.
Mike NicholsManifold Bio, Boston, MA, USA.
Erik SwansonManifold Bio, Boston, MA, USA.
Alex ReisManifold Bio, Boston, MA, USA.
Maggie PrescottManifold Bio, Boston, MA, USA.
Yue QianViva Biotech (Shanghai) Limited, Shanghai, China.ORCID 0000-0003-1989-7586
Dongming QianViva Biotech (Shanghai) Limited, Shanghai, China.ORCID 0009-0005-4463-5045
Jingjing YangViva Biotech (Shanghai) Limited, Shanghai, China.ORCID 0000-0003-0746-1953
Weiji LiViva Biotech (Shanghai) Limited, Shanghai, China.ORCID 0009-0009-7406-5759
Le LiViva Biotech (Shanghai) Limited, Shanghai, China.ORCID 0000-0001-7504-7362
Daichi ShonaiDuke University, Durham, NC, USA.ORCID 0000-0001-5430-6185
Sean GayDuke University, Durham, NC, USA.ORCID 0000-0003-0758-5016
Bhoomika Basu MallikLudwig-Maximilians-Universität München, Munich, Germany.ORCID 0000-0002-0592-4267
Ho Yeung ChimLudwig-Maximilians-Universität München, Munich, Germany.
Liurong ChenLudwig-Maximilians-Universität München, Munich, Germany.ORCID 0009-0003-4472-9792
Miguel Atienza JuanateyLudwig-Maximilians-Universität München, Munich, Germany.
Hubert KleinLudwig-Maximilians-Universität München, Munich, Germany.
Dominic RiegerLeipzig University, Leipzig, Germany.ORCID 0009-0000-0265-0304
Phillip SchlegelLeipzig University, Leipzig, Germany.ORCID 0009-0006-4640-2322
Anna U MacintyreNovo Nordisk A/S, London, UK.
Maxim SecorNovo Nordisk, Lexington, MA, USA.
Daniele GranataNovo Nordisk A/S, Copenhagen, Denmark.
Sooyoung ChaSeoul National University, Seoul, South Korea.
Zhonglin CaoNVIDIA Corporation, Santa Clara, CA, USA.ORCID 0000-0003-2096-1178
Guoqing ZhouNVIDIA Corporation, Santa Clara, CA, USA.ORCID 0000-0002-4000-8467
Tomas GeffnerNVIDIA Corporation, Santa Clara, CA, USA.ORCID 0009-0005-8116-019X
Xi ChenNVIDIA Corporation, Santa Clara, CA, USA.ORCID 0000-0002-2055-2676
Micha LivneNVIDIA Corporation, Santa Clara, CA, USA.ORCID 0000-0002-8094-7426
Zuobai ZhangNVIDIA Corporation, Santa Clara, CA, USA.ORCID 0000-0002-9773-0696
Tianjing ZhangNVIDIA Corporation, Santa Clara, CA, USA.ORCID 0000-0002-7809-6845
Kyle GionNVIDIA Corporation, Santa Clara, CA, USA.ORCID 0000-0001-5162-2481
Michael M BronsteinUniversity of Oxford, Oxford, UK.ORCID 0000-0002-1262-7252
Martin SteineggerSeoul National University, Seoul, South Korea.ORCID 0000-0001-8781-9753
Kristine DeiblerNovo Nordisk, Lexington, MA, USA.ORCID 0000-0002-2376-8456
Scott SoderlingDuke University, Durham, NC, USA.ORCID 0000-0001-7808-197X
Clara T SchoederLeipzig University, Leipzig, Germany.ORCID 0000-0002-4664-961X
Alena KhmelinskaiaLudwig-Maximilians-Universität München, Munich, Germany.ORCID 0000-0003-1584-9800
Florian HollfelderUniversity of Cambridge, Cambridge, UK.ORCID 0000-0002-1367-6312
Christian DallagoNVIDIA Corporation, Santa Clara, CA, USA.ORCID 0000-0003-4650-6181
Emine KucukbenliNVIDIA Corporation, Santa Clara, CA, USA.
Arash VahdatNVIDIA Corporation, Santa Clara, CA, USA.ORCID 0009-0005-9476-1306
Pierce OgdenManifold Bio, Boston, MA, USA.
Karsten KreisNVIDIA Corporation, Santa Clara, CA, USA.ORCID 0009-0007-0414-8650

Funding

Molecular Analysis of Developmental Brain Disorders Associated with Synaptic PathologyR01MH111684 · NIMH · DUKE UNIVERSITY · PI SCOTT H SODERLING · 2017 to 2026
$6.6M
Neuronal Kinase Signaling in Health and DiseaseR01NS147032 · NINDS · DUKE UNIVERSITY · PI SCOTT H SODERLING · 2026 to 2026
$620k
NIMH NIH HHS R01 MH111684NINDS NIH HHS R01 NS147032
6 · The paper itself

Abstract

De novo protein design has advanced rapidly, yet designing binders to polar, solvent-exposed epitopes and small, flexible ligands remains challenging. Such hydrated surfaces and flexible molecules, including carbohydrates, provide few of the hydrophobic contacts favoured by current methods and have largely resisted de novo binders. To address this challenge, here we introduce latent generative search for binder design, a novel framework that uses reward-guided search at inference time to steer the Proteína-Complexa generative model. The model codesigns sequence and structure - generating them together in a continuous latent space - and thereby removes the inverse-folding step on which current methods rely. In a screen of more than one million designs by multiplexed phage display, latent generative search produced more validated binders than every other method tested, its codesigned sequences surpassing post hoc redesign. It delivered high-affinity binders across therapeutic receptors, a viral attachment protein and intracellular signalling targets. Our approach also accessed previously untapped biology, generating the first de novo proteins that bind a free carbohydrate, including one that discriminates between blood-group antigens - a polar, flexible target class beyond the reach of current design methods.

Indexed as

carbohydrate recognitionde novo protein designgenerative modelsinference-time searchprotein binders

Identifiers

PMID42779796
PMCPMC13596280

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.